GlassScriptPhysician profile
Diane Marolda
NPI 1841278892
$3,973.94
in general payments reported to CMS, 2019-2025
30 companies · $874 in 2025
The $874 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $912 · 2023: $643 · 2024: $1,093 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $603.04 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $553.38 | 2023-2025 | Watchman Flx, Watchman, Watchman Access System |
| Janssen Pharmaceuticals, INC | $407.34 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $339.94 | 2021-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $241.57 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $235.12 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.87 | 2021-2025 | |
| Novo Nordisk INC | $200.41 | 2021-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $196.10 | 2022-2024 | Verquvo |
| Pfizer INC. | $185.44 | 2021-2025 | |
| Scpharmaceuticals INC. | $108.06 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $99.17 | 2022-2025 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $71.30 | 2024-2025 | Assure Wcd |
| Altathera Pharmaceuticals LLC | $67.29 | 2022-2024 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals International, Plc | $65.26 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $57.26 | 2021-2023 | Evkeeza |
| Arbor Pharmaceuticals, INC. | $43.88 | 2021 | |
| Daiichi Sankyo INC. | $38.49 | 2022 | |
| Edwards Lifesciences Corporation | $37.48 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Philips North America LLC | $36.92 | 2023 | |
| United Therapeutics Corporation | $30.05 | 2021 | |
| Biomerieux INC | $23.12 | 2021 | |
| Bridgebio Pharma, INC. | $18.40 | 2025 | Attruby |
| Atricure, INC. | $17.07 | 2025 | Atriclip Laa Exclusion System |
| Azurity Pharmaceuticals, INC. | $16.97 | 2024 | Edarbi |
| Acarix USA INC. | $15.69 | 2023 | Cadscor System |
| Cmp Pharma, INC. | $15.68 | 2022 | |
| Lilly USA, LLC | $14.80 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.51 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Marolda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.